Democracy in action! This month's GU Cast Journal Club papers were chosen by an audience vote at our GU Cast Live Event at EAU in London.
Therefore today we focus on first, the landmark proPSMA paper which established the superior accuracy of PSMA PET/CT for staging unfavourable intermediate and high-risk prostate cancer (Lancet 2020). Then for something completely different, we dig out a paper called "Penile fractures - the merry price of Christmas", published in BJUI 2020. Thanks very much to our live audience for this one!

We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado and Dr Elena Berg who joins us in studio for the first time. Elena has just moved to Melbourne to join Carlos doing a Fellowship with GU Cast hosts, Renu Eapen and Declan Murphy.

Links to papers below:
1. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020

2. Penile fractures: the price of a Merry Christmas BJUI 2023

GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.

Even better on our YouTube channel

About GU Cast Journal Club:
Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology
. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner
. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

The trial they said would never be done! Huge congrats to the Alliance for Clinical Trials in Oncology who have recently opened the ASPIRE trial, a phase III randomised trial of ADT + apalutamide (doublet), vs ADT + apalutamide + docetaxel chemotherapy (triplet) for men with mHSPC. 1200 men will be recruited from more than 300 sites across the US with many sites already open and recruiting. This is the key trial which will answer the question of whether there is an overall survival benefit of adding chemo to the ADT/ARPI doublet which we all agree is standard of care.
We chat with study chair Dr Deepak Kilari (Medical College of Wisconsin) and Dr Rana McKay (University of California San Diego), and learn all about the rationale for ASPIRE, the study design, and the novel genomic stratification factors.
Your usual hosts are Renu Eapen and (chemo-sceptic) Declan Murphy!

This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson Pharmaceuticals.

Links:
Alliance website with study details
Urology Times coverage
Clinical Trials registration

Our biggest live show to date! Taking to the huge eUro 2 auditorium at this month's EAU Annual Meeting in London, Declan and Renu bring you a fast-paced, high-energy session packed with favourite guests, controversial topics, behind-the-scenes stories, and lots of great giveaways, all boosted by having hundreds of our loyal supporters there in the audience with us.

Huge thanks to Maarten Albersen and all at the EAU Scientific Office for this invitation, and to everyone at MediAVentures, M-Events, Congress Consultants, Soma Studios and CMDM Media for helping us put it together. And to our own team including David Chen, Carlos Delgado, and Elena Berg for their help and for being with us in London.

This one for sure best enjoyed on our YouTube channel